Pathophysiology of systemic sclerosis: current understanding and new insights

References

• Gabrielli A, Avvedimento EV, Krieg T. Scleroderma. N Engl J Med. 2009;360:1989–2003.
   PubMed Web of Science ®Google Scholar
• Watad A, Rosenberg V, Tiosano S, et al. Silicone breast implants and the risk of autoimmune/rheumatic disorders: a real-world analysis. Int J Epidemiol. 2018;47:1846–1854.
   PubMed Web of Science ®Google Scholar
• Cutolo M, Sulli A, Smith V. Assessing microvascular changes in systemic sclerosis diagnosis and management. Nat Rev Rheumatol. 2010;6:578–587.
   PubMed Web of Science ®Google Scholar
• Bhattacharyya S, Wei J, Varga J. Understanding fibrosis in systemic sclerosis: shifting paradigms, emerging opportunities. Nat Rev Rheumatol. 2012;8:42–54.
   Web of Science ®Google Scholar
• Wigley FM, Flavahan NA. Raynaud’s Phenomenon. N Engl J Med. 2016;375:556–565.
   PubMed Web of Science ®Google Scholar
• Cutolo M, Pizzorni C, Sulli A. Identification of transition from primary Raynaud’s phenomenon to secondary Raynaud’s phenomenon by nailfold videocapillaroscopy: comment on the article by Hirschl et al. Arthritis Rheum. 2007;56:2102–2103.
   PubMedGoogle Scholar
• Cutolo M, Smith V, Furst DE, et al. Points to consider-Raynaud’s phenomenon in systemic sclerosis. Rheumatology (Oxford). 2017;56(suppl_5):v45–v48.
   PubMedGoogle Scholar
• Mostmans Y, Cutolo M, Giddelo C, et al. The role of endothelial cells in the vasculopathy of systemic sclerosis: a systematic review. Autoimmun Rev. 2017;16:774–786.
   PubMed Web of Science ®Google Scholar
• Martin ER, Brenner BM, Ballermann BJ. Heterogeneity of cell surface endothelin receptors. J Biol Chem. 1990;265:14044–14049.
   PubMed Web of Science ®Google Scholar
• Lin HY, Kaji EH, Winkel GK, et al. Cloning and functional expression of a vascular smooth muscle endothelin 1 receptor. Proc Natl Acad Sci U S A. 1991;88:3185–3189.
   PubMed Web of Science ®Google Scholar
• Takayanagi R, Kitazumi K, Takasaki C, et al. Presence of non-selective type of endothelin receptor on vascular endothelium and its linkage to vasodilation. FEBS Lett. 1991;282:103–106.
   PubMed Web of Science ®Google Scholar
• Bruni C, Frech T, Manetti M, et al. Vascular leaking, a pivotal and early pathogenetic event in systemic sclerosis: should the door be closed? Front Immunol. 2018;9:2045.
   PubMed Web of Science ®Google Scholar
• Vega AV, Avila G. CGRP, a vasodilator neuropeptide that stimulates neuromuscular transmission and EC coupling. Curr Vasc Pharmacol. 2010;8:394–403.
   PubMed Web of Science ®Google Scholar
• Iwamoto N, Distler O. Molecular targets for therapy in systemic sclerosis. Fibrogenesis Tissue Repair. 2012;5(Suppl 1):S19.
   PubMedGoogle Scholar
• Flavahan NA. A vascular mechanistic approach to understanding Raynaud phenomenon. Nat Rev Rheumatol. 2015;11:146–158.
   PubMed Web of Science ®Google Scholar
• Distler O, Del Rosso A, Giacomelli R, et al. Angiogenic and angiostatic factors in systemic sclerosis: increased levels of vascular endothelial growth factor are a feature of the earliest disease stages and are associated with the absence of fingertip ulcers. Arthritis Res. 2002;4:R11.
   PubMedGoogle Scholar
• Distler O, Distler JH, Scheid A, et al. Uncontrolled expression of vascular endothelial growth factor and its receptors leads to insufficient skin angiogenesis in patients with systemic sclerosis. Circ Res. 2004;95:109–116.
   PubMed Web of Science ®Google Scholar
• Manetti M, Guiducci S, Romano E, et al. Overexpression of VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, leads to insufficient angiogenesis in patients with systemic sclerosis. Circ Res. 2011;109:e14–26.
   PubMed Web of Science ®Google Scholar
• Manetti M, Guiducci S, Romano E, et al. Increased plasma levels of the VEGF165b splice variant are associated with the severity of nailfold capillary loss in systemic sclerosis. Ann Rheum Dis. 2013;72:1425–1427.
   PubMed Web of Science ®Google Scholar
• Hirigoyen D, Burgos PI, Mezzano V, et al. Inhibition of angiogenesis by platelets in systemic sclerosis patients. Arthritis Res Ther. 2015 Nov;19(17):332.
   Google Scholar
• Qiu Y, Hoareau-Aveilla C, Oltean S, et al. The anti-angiogenic isoforms of VEGF in health and disease. Biochem Soc Trans. 2009;37(Pt 6):1207–1213.
   PubMed Web of Science ®Google Scholar
• Ganta VC, Choi M, Farber CR, et al. Antiangiogenic VEGF165b regulates macrophage polarization via S100A8/S100A9 in peripheral artery disease. Circulation. 2019;139:226–242.
   PubMed Web of Science ®Google Scholar
• Piera-Velazquez S, Jimenez SA. Endothelial to mesenchymal transition: role in physiology and in the pathogenesis of human diseases. Physiol Rev. 2019;99:1281–1324.
   PubMed Web of Science ®Google Scholar
• Piera-Velazquez S, Mendoza FA, Jimenez SA. Endothelial to mesenchymal transition (EndoMT) in the pathogenesis of human fibrotic diseases. J Clin Med. 2016;5:45.
   Web of Science ®Google Scholar
• Cipriani P, Di Benedetto P, Ruscitti P, et al. Impaired endothelium-mesenchymal stem cells cross-talk in systemic sclerosis: a link between vascular and fibrotic features. Arthritis Res Ther. 2014;16:442.
   PubMed Web of Science ®Google Scholar
• Cipriani P, Guiducci S, Miniati I, et al. Impairment of endothelial cell differentiation from bone marrow-derived mesenchymal stem cells: new insight into the pathogenesis of systemic sclerosis. Arthritis Rheum. 2007;56:1994–2004.
   PubMed Web of Science ®Google Scholar
• Hegner B, Schaub T, Catar R, et al. Intrinsic Deregulation Of Vascular Smooth Muscle And Myofibroblast Differentiation In Mesenchymal Stromal Cells From Patients With Systemic Sclerosis. PLoS One. 2016;11:e0153101.
   PubMed Web of Science ®Google Scholar
• Cipriani P, Di Benedetto P, Ruscitti P, et al. Perivascular cells in diffuse cutaneous systemic sclerosis overexpress activated ADAM12 and are involved in myofibroblast transdifferentiation and development of fibrosis. J Rheumatol. 2016;43:1340–1349.
   PubMed Web of Science ®Google Scholar
• Dulauroy S, Di Carlo SE, Langa F, et al. Lineage tracing and genetic ablation of ADAM12(+) perivascular cells identify a major source of profibrotic cells during acute tissue injury. Nat Med. 2012;18:1262–1270.
   PubMed Web of Science ®Google Scholar
• Kuwana M, Okazaki Y. Quantification of circulating endothelial progenitor cells in systemic sclerosis: a direct comparison of protocols. Ann Rheum Dis. 2012;71:617–620.
   PubMed Web of Science ®Google Scholar
• Hristov M, Weber C. Endothelial progenitor cells: characterization, pathophysiology, and possible clinical relevance. J Cell Mol Med. 2004;8:498–508.
   PubMed Web of Science ®Google Scholar
• Del Papa N, Pignataro F. The role of endothelial progenitors in the repair of vascular damage in systemic sclerosis. Front Immunol. 2018;9:1383.
   PubMed Web of Science ®Google Scholar
• Del Papa N, Quirici N, Scavullo C, et al. Antiendothelial cell antibodies induce apoptosis of bone marrow endothelial progenitors in systemic sclerosis. J Rheumatol. 2010;37:2053–2063.
   PubMed Web of Science ®Google Scholar
• Arends SJ, Damoiseaux JG, Duijvestijn AM, et al. Immunoglobulin G anti-endothelial cell antibodies: inducers of endothelial cell apoptosis in pulmonary arterial hypertension? Clin Exp Immunol. 2013;174:433–440.
   PubMed Web of Science ®Google Scholar
• Sgonc R, Gruschwitz MS, Dietrich H, et al. Endothelial cell apoptosis is a primary pathogenetic event underlying skin lesions in avian and human scleroderma. J Clin Invest. 1996;98:785–792.
   PubMed Web of Science ®Google Scholar
• Skaug B, Assassi S. Type I interferon dysregulation in systemic sclerosis. Cytokine. 2019 Jan 23. pii:S1043-4666(19)30006-7.
   PubMedGoogle Scholar
• Boin F1, De Fanis U, Bartlett SJ, et al. T cell polarization identifies distinct clinical phenotypes in scleroderma lung disease. Arthritis Rheum. 2008;58:1165–1174.
   PubMed Web of Science ®Google Scholar
• Slobodin G, Rimar D. Regulatory T cells in systemic sclerosis: a comprehensive review. Clin Rev Allergy Immunol. 2017;52:194–201.
   PubMed Web of Science ®Google Scholar
• Chizzolini C, Boin F. The role of the acquired immune response in systemic sclerosis. Semin Immunopathol. 2015;37:519–528.
   PubMed Web of Science ®Google Scholar
• MacDonald KG, Dawson NA, Huang Q, et al. Regulatory T cells produce profibrotic cytokines in the skin of patients with systemic sclerosis. J Allergy Clin Immunol. 2015;135:946, e9.
   PubMed Web of Science ®Google Scholar
• Manetti M, Pratesi S, Romano E, et al. Angiogenic T cell expansion correlates with severity of peripheral vascular damage in systemic sclerosis. PLoS One. 2017;12:e0183102.
   PubMed Web of Science ®Google Scholar
• Khan K, Xu S, Nihtyanova S, et al. Clinical and pathological significance of interleukin 6 overexpression in systemic sclerosis. Ann Rheum Dis. 2012;71:1235–1242.
   PubMed Web of Science ®Google Scholar
• Hasegawa M, Asano Y, Endo H, et al. Serum chemokine levels as prognostic markers in patients with early systemic sclerosis: a multicenter, prospective, observational study. Mod Rheumatol. 2013;23:1076–1084.
   PubMed Web of Science ®Google Scholar
• Ah Kioon MD, Tripodo C, Fernandez D, et al. Plasmacytoid dendritic cells promote systemic sclerosis with a key role for TLR8. Sci Transl Med. 2018;10:423–430.
   Web of Science ®Google Scholar
• Mehra S, Walker J, Patterson K, et al. Autoantibodies in systemic sclerosis. Autoimmun Rev. 2013;12:340–354.
   PubMed Web of Science ®Google Scholar
• Steen VD. Autoantibodies in systemic sclerosis. Semin Arthritis Rheum. 2005;35:35–42.
   PubMed Web of Science ®Google Scholar
• Senecal JL, Henault J, Raymond Y. The pathogenic role of autoantibodies to nuclear autoantigens in systemic sclerosis (scleroderma). J Rheumatol. 2005;32:1643–1649.
   PubMed Web of Science ®Google Scholar
• Henault J, Robitaille G, Senecal JL, et al. DNAtopoisomerase I binding to fibroblasts induces monocyte adhesion and activation in the presence of anti-topoisomerase I autoantibodies from systemic sclerosis patients. Arthritis Rheum. 2006;54:963–973.
   PubMed Web of Science ®Google Scholar
• Weiner ES, Hildebrandt S, Senecal JL, et al. Prognostic significance of anticentromere antibodies and anti-topoisomerase I antibodies in Raynaud’s disease. A prospective study. Arthritis Rheum. 1991;34:68–77.
   PubMedGoogle Scholar
• Hamaguchi Y, Kodera M, Matsushita T, et al. Clinical and immunologic predictors of scleroderma renal crisis in Japanese systemic sclerosis patients with anti-RNA polymerase iii autoantibodies. Arthritis Rheumatol. 2015;67:1045–1052.
   PubMed Web of Science ®Google Scholar
• Cabral-Marques O, Riemekasten G. Functional autoantibodies targeting G protein-coupled receptors in rheumatic diseases. Nat Rev Rheumatol. 2017;13:648–656.
   PubMed Web of Science ®Google Scholar
• Dragun D, Distler JH, Riemekasten G, et al. Stimulatory autoantibodies to platelet-derived growth factor receptors in systemic sclerosis: what functional autoimmunity could learn from receptor biology. Arthritis Rheum. 2009;60:907–911.
   PubMedGoogle Scholar
• Riemekasten G, Philippe A, Nather M, et al. Involvement of functional autoantibodies against vascular receptors in systemic sclerosis. Ann Rheum Dis. 2011;70:530–536.
   PubMed Web of Science ®Google Scholar
• Becker MO, Kill A, Kutsche M, et al. Vascular receptor autoantibodies in pulmonary arterial hypertension associated with systemic sclerosis. Am J Respir Crit Care Med. 2014;190:808–817.
   PubMed Web of Science ®Google Scholar
• Mihai C, Tervaert JW. Anti-endothelial cell antibodies in systemic sclerosis. Ann Rheum Dis. 2010;69:319–324.
   PubMed Web of Science ®Google Scholar
• Carvalho D, Co S, Cm B, et al. IgG antiendothelial cell autoantibodies from scleroderma patients induce leukocyte adhesion to human vascular endothelial cells in vitro. Induction of adhesion molecule expression and involvement of endothelium-derived cytokines. J Clin Invest. 1996;97:111–119.
   PubMed Web of Science ®Google Scholar
• Wolf SI, Howat S, Abraham DJ, et al. Agonistic anti-ICAM-1 antibodies in scleroderma: activation of endothelial pro-inflammatory cascades. Vasc Pharmacol. 2013;59:19–26.
   PubMed Web of Science ®Google Scholar
• Manetti M. Deciphering the alternatively activated (M2) phenotype of macrophages in scleroderma. Exp Dermatol. 2015;24:576–578.
   PubMed Web of Science ®Google Scholar
• Funes SC, Rios M, Escobar-Vera J, et al. Implications of macrophage polarization in autoimmunity. Immunology. 2018;154:186–195.
   PubMed Web of Science ®Google Scholar
• Soldano S, Pizzorni C, Paolino S, et al. Alternatively activated (M2) macrophage phenotype is inducible by endothelin-1 in cultured human macrophages. PLoS One. 2016;11:e0175238.
   Web of Science ®Google Scholar
• Christmann RB, Lafyatis R. The cytokine language of monocytes and macrophages in systemic sclerosis. Arthritis Res Ther. 2010;12:146–152.
   PubMed Web of Science ®Google Scholar
• Christmann RB, Sampaio-Barros P, Stifano G, et al. Association of interferon- and transforming growth factor beta-regulated genes and macrophage activation with systemic sclerosisrelated progressive lung fibrosis. Arthritis Rheumatol. 2014;66:714–725.
   PubMed Web of Science ®Google Scholar
• Hsu E, Shi H, Jordan RM, et al. Lung tissues in patients with systemic sclerosis have gene expression patterns unique to pulmonary fibrosis and pulmonary hypertension. Arthritis Rheum. 2011;63:783–794.
   PubMed Web of Science ®Google Scholar
• Enomoto Y, Suzuki Y, Hozumi H, et al. Clinical significance of soluble CD163 in polymyositis-related or dermatomyositisrelated interstitial lung disease. Arthritis Res Ther. 2017;19:9.
   PubMed Web of Science ®Google Scholar
• Jiang Z, Zhu L. Update on the role of alternatively activated macrophages in asthma. J Asthma Allergy. 2016;9:101–107.
   PubMed Web of Science ®Google Scholar
• Bazzan E, Turato G, Tinè M, et al. Dualpolarization of human alveolar macrophages progressively increases with smoking and COPD severity. Respir Res. 2017;18:40–47.
   PubMed Web of Science ®Google Scholar
• Groves AM, Johnston CJ, Misra RS, et al. Effects of IL-4 on pulmonary fibrosis and the accumulation and phenotype of macrophage subpopulations following thoracic irradiation. Int J Radiat Biol. 2016;92:754–765.
   PubMed Web of Science ®Google Scholar
• Deckman JM, Kurkjian CJ, McGillis JP, et al. Pneumocystis infection alters the activation state of pulmonary macrophages. Immunobiology. 2017;222:188–197.
   PubMed Web of Science ®Google Scholar
• Huang F, Chen Z, Chen H, et al. Cypermethrin promotes lung cancer metastasis via modulation of macrophage polarization by targeting MicroRNA-155/Bcl6. Toxicol Sci. 2018;163:454–465.
   PubMed Web of Science ®Google Scholar
• Mantovani A, Biswas SK, Galdiero MR, et al. Macrophage plasticity and polarization in tissue repair and remodelling. J Pathol. 2013;229:176–185.
   PubMed Web of Science ®Google Scholar
• Stifano G, Christmann RB. Macrophage involvement in systemic sclerosis: do we need more evidence? Curr Rheumatol Rep. 2016;18:2.
   PubMed Web of Science ®Google Scholar
• Gundra UM, Girgis NM, Ruckerl D, et al. Alternatively activated macrophages derived from monocytes and tissue macrophages areì phenotypically and functionally distinct. Blood. 2014;123:e110–22.
   PubMed Web of Science ®Google Scholar
• Mosser DM, Edwards JP. Exploring the full spectrum of macrophage activation. Nat Rev Immunol. 2008;8:958–969.
   PubMed Web of Science ®Google Scholar
• Mitsi E, Kamng’ona R, Rylance J, et al. Human alveolar macrophages predominately express combined classical M1 and M2 surface markers in steady state. Respir Res. 2018;19:66.
   PubMed Web of Science ®Google Scholar
• Soldano S, Trombetta AC, Contini P, et al. Increase in circulating cells coexpressing M1 and M2 macrophage surface markers in patients with systemic sclerosis. Ann Rheum Dis. 2018;77:1842–1845.
   PubMed Web of Science ®Google Scholar
• Trombetta AC, Soldano S, Contini P, et al. A circulating cell population showing both M1 and M2 monocyte/macrophage surface markers characterizes systemic sclerosis patients with lung involvement. Respir Res. 2018;19:186–197.
   PubMed Web of Science ®Google Scholar
• van Caam A, Vonk M, van Den Hoogen F, et al. Unraveling SSc pathophysiology; the myofibroblast. Front Immunol. 2018;9:2452–2463.
   PubMed Web of Science ®Google Scholar
• Bhattacharyya S, Tamaki Z, Wang W, et al. FibronectinEDA promotes chronic cutaneous fibrosis through toll-like receptor signaling. Sci Transl Med. 2014;16:232ra50.
   Google Scholar
• Bhattacharyya S, Wang W, Morales-Nebreda L, et al. Tenascin-C drives persistence of organ fibrosis. Nat Commun. 2016;7:11703.
   PubMed Web of Science ®Google Scholar
• Cutolo M. Tenascin and arthritis. Br J Rheumatol. 1994;33:197–200.
   PubMedGoogle Scholar
• Cutolo M, Picasso M, Ponassi M, et al. Tenascin and fibronectin distribution in human normal and pathological synovium. J Rheumatol. 1992;19:1439–1447.
   PubMed Web of Science ®Google Scholar
• Cutolo M, Soldano S, Paolino S. Potential roles for tenascin in (very) early diagnosis and treatment of rheumatoid arthritis. Ann Rheum Dis. 2019 Feb 1. doi:10.1136/annrheumdis-2019-215063
   Google Scholar
• Ho Y, Lagares D, Tager AM, et al. a lethal component of systemic sclerosis. Nat Rev Rheumatol. 2014;10:390–402.
   PubMed Web of Science ®Google Scholar
• Chizzolini C, Brembilla NC, Montanari E, et al. Fibrosis and immune dysregulation in systemic sclerosis. Autoimmun Rev. 2011;10:276–281.
   PubMed Web of Science ®Google Scholar
• Raker V, Haub J, Stojanovic A, et al. Early inflammatory players in cutanous fibrosis. J Dermatol Sci. 2017;87:228–235.
   PubMed Web of Science ®Google Scholar
• O’Reilly S. miRNA-29a in systemic sclerosis: a valid target. Autoimmunity. 2015;48:511–512.
   PubMed Web of Science ®Google Scholar
• Maurer B, Stanczyk J, Jüngel A, et al. MicroRNA 29, a key regulator of collagen expression in systemic sclerosis. Arthritis Rheum. 2010;62:1733–1743.
   PubMed Web of Science ®Google Scholar
• Artlett CM, Sassi-Gaha S, Hope JL, et al. Mir-155 is overexpressed in systemic sclerosis fibroblasts and is required for NLRP3 inflammasome-mediated collagen synthesis during fibrosis. Arthritis Res Ther. 2017;19:144–149.
   PubMed Web of Science ®Google Scholar
• Varga J, Pasche B. Transforming growth factor β as a therapeutic target in systemic sclerosis. Nat Rev Rheumatol. 2009;5:200–206.
   PubMed Web of Science ®Google Scholar
• Carthy JM. TGF-β signaling and the control of myofibroblast differentiation: implications for chronic inflammatory disorders. J Cell Physiol. 2018;233:98–106.
   PubMed Web of Science ®Google Scholar
• Asano Y, Ihn H, Yamane K, et al. Impaired SMAD7–SMURF-mediated negative regulation of TGF-β signaling in scleroderma fibroblasts. J Clin Invest. 2004;113:253–264.
   PubMed Web of Science ®Google Scholar
• Zhou F, Drabsch Y, Dekker TJ, et al. Nuclear receptor NR4A1 promotes breast cancer invasion and metastasis by activating TGF β signalling. Nat Commun. 2014;5:3388.
   PubMed Web of Science ®Google Scholar
• Cipriani P, Di Benedetto P, Ruscitti P, et al. Macitentan inhibits the transforming growth factor-β profibrotic action, blocking the signaling mediated by the ETR/TβRI complex in systemic sclerosis dermal fibroblasts. Arthritis Res Ther. 2015;17:247–254.
   PubMed Web of Science ®Google Scholar
• Shi-Wen X, Kennedy L, Renzoni EA, et al. Endothelin is a downstream mediator of profibrotic responses to transforming growth factor β in human lung fibroblasts. Arthritis Rheum. 2007;56:4189–4194.
   PubMed Web of Science ®Google Scholar
• Kawaguchi Y, Suzuki K, Hara M, et al. Increased endothelin-1 production in fibroblasts derived from patients with systemic sclerosis. Ann Rheum Dis. 1994;53:506–510.
   PubMed Web of Science ®Google Scholar
• Shi-Wen X, Denton CP, Dashwood MR, et al. Fibroblast matrix gene expression and connective tissue remodelling: role of endothelin-1. J Invest Dermatol. 2001;116:417–425.
   PubMed Web of Science ®Google Scholar
• Soldano S, Montagna P, Brizzolara R, et al. Endothelin receptor antagonists: effects on extracellular matrix synthesis in primary cultures of skin fibroblasts from systemic sclerosis patients. Reumatismo. 2012;64:326–334.
   PubMedGoogle Scholar
• Shimizu M, Ishibashi Y, Taki F, et al. Endothelin(B) receptor blocker inhibits high glucose-induced synthesis of fibronectin in human peritoneal mesothelial cells. Perit Dial Int. 2006;26:393–401.
   PubMed Web of Science ®Google Scholar
• Denton CP. Advances in pathogenesis and treatment of systemic sclerosis. Clin Med (Lond). 2016;16:55–60.
   PubMed Web of Science ®Google Scholar
• Cutolo M, Sulli A, Smith V. Evaluating microangiopathy in systemic sclerosis: what have we learnt and what is left to discover? Expert Rev Clin Immunol. 2011;7:395–397.
   PubMed Web of Science ®Google Scholar
• Piera-Velazquez S, Li Z, Jimenez SA. Role of endothelial-mesenchymal transition (EndoMT) in the pathogenesis of fibrotic disorders. Am J Pathol. 2011;179:1074–1080.
   PubMed Web of Science ®Google Scholar
• Chen PY, Qin L, Baeyens N, et al. Endothelial-to-mesenchymal transition drives atherosclerosis progression. J Clin Invest. 2015;125:4514–4528.
   PubMed Web of Science ®Google Scholar
• Arciniegas E, Frid MG, Douglas IS, et al. Perspectives on endothelial-to-mesenchymal transition: potential contribution to vascular remodeling in chronic pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol. 2007;293:L1–8.
   PubMed Web of Science ®Google Scholar
• Li J, Bertram JF. Endothelial-myofibroblast transition, a new player in diabetic renal fibrosis. Nephrology (Carlton). 2010;15:507–512.
   PubMed Web of Science ®Google Scholar
• Lafyatis R. Transforming growth factor β—at the centre of systemic sclerosis. Nat Rev Rheumatol. 2014;10:706–719.
   PubMed Web of Science ®Google Scholar
• Rodríguez-Pascual F, Busnadiego O, González-Santamaría J. The profibrotic role of endothelin-1: is the door still open for the treatment of fibrotic diseases? Life Sci. 2014;118:156–164.
   PubMed Web of Science ®Google Scholar
• Soldano S, Paolino S, Pizzorni C, et al. Dual endothelin receptor antagonists contrast the effects induced by endothelin-1 on cultured human microvascular endothelial cells. Clin Exp Rheumatol. 2017;35:484–493.
   PubMed Web of Science ®Google Scholar
• Corallo C, Cutolo M, Kahaleh B, et al. Bosentan and macitentan prevent the endothelial-to-mesenchymal transition (EndoMT) in systemic sclerosis: in vitro study. Arthritis Res Ther. 2016;18:228.
   PubMed Web of Science ®Google Scholar
• Marangoni RG, Korman BD, Wei J, et al. Myofibroblasts in murine cutaneous fibrosis originate from adiponectin-positive intradermal progenitors. Arthritis Rheumatol. 2015;67:1062–1073.
   PubMed Web of Science ®Google Scholar
• Andrade ZDA, de-Oliveira-Filho J, Fernandes AL. Interrelationship between adipocytes and fibroblasts during acute damage to the subcutaneous adipose tissue of rats: an ultrastructural study. Braz J Med Biol Res. 1998;31:659–664.
   PubMed Web of Science ®Google Scholar
• Liu S, Yang Y, Wu J. TNFα-induced up-regulation of miR-155 inhibits adipogenesis by down-regulating early adipogenic transcription factors. Biochem Biophys Res Commun. 2011;414:618–624.
   PubMed Web of Science ®Google Scholar
• Chen Y, Siegel F, Kipschull S, et al. MiR-155 regulates differentiation of brown and beige adipocytes via a bistable circuit. Nat Commun. 2013;4:1769.
   PubMed Web of Science ®Google Scholar
• Kruglikov IL. Interfacial adipose tissue in systemic sclerosis. Curr Rheumatol Rep. 2017;19:4–12.
   PubMed Web of Science ®Google Scholar
• Avouac J, Lepri G, Smith V, et al. Sequential nailfold videocapillaroscopy examinations have responsiveness to detect organ progression in systemic sclerosis. Semin Arthritis Rheum. 2017;47:86–94.
   PubMed Web of Science ®Google Scholar
• Smith V, Thevissen K, Trombetta AC, et al. EULAR study group on microcirculation in rheumatic diseases. Nailfold capillaroscopy and clinical applications in systemic sclerosis. Microcirculation. 2016;23:364–372.
   PubMed Web of Science ®Google Scholar
• Burmester GR, Bijlsma JWJ, Cutolo M, et al. Managing rheumatic and musculoskeletal diseases - past, present and future. Nat Rev Rheumatol. 2017;13:443–448.
   PubMed Web of Science ®Google Scholar
• Smith V, Scirè CA, Talarico R, et al. Systemic sclerosis: state of the art on clinical practice guidelines. RMD Open. 2018 Oct 18;4(Suppl 1):e000782.
   PubMedGoogle Scholar
• Pizzorni C, Sulli A, Paolino S, et al. Progression of organ involvement in systemic sclerosis patients with persistent “late” nailfold capillaroscopic pattern of microangiopathy: a prospective study. J Rheumatol. 2017;44:1941–1942.
   PubMed Web of Science ®Google Scholar
• Frerix M, Meier FM, Hermann W, et al. Therapeutic management in early disease stages of systemic sclerosis: early diagnosis - early symptoms - early problems. Z Rheumatol. 2013;72:960–969.
   PubMed Web of Science ®Google Scholar
• Cutolo M, Ruaro B, Montagna P, et al. Effects of selexipag and its active metabolite in contrasting the profibrotic myofibroblast activity in cultured scleroderma skin fibroblasts. Arthritis Res Ther. 2018;20:77.
   PubMed Web of Science ®Google Scholar
• Cutolo M, Montagna P, Brizzolara R, et al. Effects of macitentan and its active metabolite on cultured human systemic sclerosis and control skin fibroblasts. J Rheumatol. 2015;42:456–463.
   PubMed Web of Science ®Google Scholar
• Elhai M, Meunier M, Matucci-Cerinic M, et al. Outcomes of patients with systemic sclerosis-associated polyarthritis and myopathy treated with tocilizumab or abatacept: a EUSTAR observational study. Ann Rheum Dis. 2013;72:1217–1220.
   PubMed Web of Science ®Google Scholar
• Ponsoye M, Frantz C, Ruzehaji N, et al. Treatment with abatacept prevents experimental dermal fibrosis and induces regression of established inflammation-driven fibrosis. Ann Rheum Dis. 2016;75:2142–2149.
   PubMed Web of Science ®Google Scholar
• Cutolo M, Soldano S, Montagna P, et al. Effects of CTLA4-Ig treatment on circulating fibrocytes and skin fibroblasts from the same systemic sclerosis patients: an in vitro assay. Arthritis Res Ther. 2018;20:157.
   PubMed Web of Science ®Google Scholar
• Smith V, Van Praet JT, Vandooren B, et al. Rituximab in diffuse cutaneous systemic sclerosis: an open-label clinical and histopathological study. Ann Rheum Dis. 2010;69:193–197.
   PubMed Web of Science ®Google Scholar
• Smith V, Piette Y, van Praet JT, et al. Two-year results of an open pilot study of a 2-treatment course with rituximab in patients with early systemic sclerosis with diffuse skin involvement. J Rheumatol. 2013;40:52–57.
   PubMed Web of Science ®Google Scholar
• Smith V, Pizzorni C, Riccieri V, et al. Stabilization of microcirculation in patients with early systemic sclerosis with diffuse skin involvement following rituximab treatment: an open-label study. J Rheumatol. 2016;43:995–996.
   PubMed Web of Science ®Google Scholar
• Filaci G, Cutolo M, Scudeletti M, et al. Cyclosporin A and iloprost treatment of systemic sclerosis: clinical results and interleukin-6 serum changes after 12 months of therapy. Rheumatology (Oxford). 1999;38:992–996.
   PubMed Web of Science ®Google Scholar
• Miniati I, Guiducci S, Conforti ML, et al. Autologous stem cell transplantation improves microcirculation in systemic sclerosis. Ann Rheum Dis. 2009;68:94–98.
   PubMed Web of Science ®Google Scholar